Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 17/20 | 0.55 |
| ▸ | AURKA | O14965 | 3/20 | 0.54 |
| ▸ | PDE4A | P27815 | 8/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.53 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7160110 | 0.88 | PDE5A (0.56) | PDE5AAURKAPDE4APDE4BPDE4C | |
| SCHEMBL7153868 | 0.83 | METAP2 (0.48) | PDE5AAURKAPDE4APDE4BPDE4C | |
| SCHEMBL7160066 | 0.82 | NPC1 (0.54) | — | |
| SCHEMBL7548148 | 0.80 | KDM4E (0.40) | PDE5A | |
| SCHEMBL7550880 | 0.79 | AURKA (0.71) | AURKAMETAP2METAP1 | |
| SCHEMBL8556563 | 0.78 | METAP2 (0.43) | PDE5AAURKAPDE4APDE4BPDE4C | |
| SCHEMBL7159177 | 0.78 | PDE5A (0.45) | PDE5AAURKAPDE4APDE4BPDE4C | |
| SCHEMBL7156591 | 0.77 | PDE5A (0.43) | PDE5AAURKAMETAP2METAP1 | |
| SCHEMBL7155458 | 0.77 | AURKA (0.73) | PDE5AAURKAMETAP2METAP1 | |
| SCHEMBL7553105 | 0.77 | PDE5A (0.55) | PDE5AAURKAMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6534521-B2 | Useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | WARNER-LAMBERT COMPANY (US) | 2002-07-25 | — | — | US | disclosed |
| US-6348487-B1 | ANTIINFLAMMATORY AGENTS, ATHEROSCLEROSIS, RESTINOSIS AND IMMUNE DISORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6184235-B1 | MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1) ANTAGONIST FOR TREATMENT OF INFLAMMATORY DISEASES, ATHEROSCLEROSIS, RESTENOSIS, AUTOIMMUNE DISEASES, ORGAN TRANSPLANT REJECTION IN MAMMALS | WARNER-LAMBERT COMPANY | 2001-02-06 | — | — | US | disclosed |
| EP-0927167-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998006703-A1 | 2-PHENYL BENZIMIDAZOLE DERIVATIVES AS MCP-1 ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099054-A1 | 2-phenyl benzimidazole derivatives as MCP-1 antagonists | CCR1, CCR2, CCR8 | PDE5A 3671/4885AURKA 4675/4885PDE4A 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.